Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)

Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Corcept Therapeutics today and set a price target of $110.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Nash is a 5-star analyst with an average return of 26.0% and a 51.22% success rate. Nash covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Kiniksa Pharmaceuticals, and Travere Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corcept Therapeutics with a $91.00 average price target.

Based on Corcept Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $164.9 million and a GAAP net loss of $31.2 million. In comparison, last year the company earned a revenue of $157.21 million and had a net profit of $20.55 million

Based on the recent corporate insider activity of 143 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CORT in relation to earlier this year. Most recently, in March 2026, Leonard G. Baker, a Director at CORT bought 100,000.00 shares for a total of $3,313,562.08.